Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

In this randomized phase II study (GEM-KyCyDex, clinicaltrials gov. Identifier: NCT03336073), the combination of weekly carfilzomib 70 mg/m(2), cyclophosphamide and dexamethasone (KCd) was compared to carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM) after 1-3 prior l...

Descripción completa

Detalles Bibliográficos
Autores principales: Puertas, Borja, González-Calle, Verónica, Sureda, Anna, Moreno, María José, Oriol, Albert, González, Esther, Rosiñol, Laura, López, Jordi, Escalante, Fernando, Martínez-Lopez, Joaquín, Carrillo, Estrella, Clavero, Esther, Ríos-Tamayo, Rafael, Rey-Bua, Beatriz, González-Rodríguez, Ana Pilar, Dourdil, Victoria, de Arriba, Felipe, González, Sonia, Pérez-de-Oteyza, Jaime, Hernández, Miguel T., García-Mateo, Aránzazu, Bargay, Joan, Bladé, Joan, Lahuerta, Juan José, San Miguel, Jesús F., Ocio, Enrique M., Mateos, María-Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Plasma Cell Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542845/
https://www.ncbi.nlm.nih.gov/pubmed/37102598
http://dx.doi.org/10.3324/haematol.2022.282490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542845/
https://www.ncbi.nlm.nih.gov/pubmed/37102598
http://dx.doi.org/10.3324/haematol.2022.282490

Ejemplares similares